Main content

    MMC Available Clinical Trials

    Breadcrumbs Navigation: Cancer Services > Treatment > Clinical Trials at MMC > You are here: MMC Available Trials

     


    Note: As of January 2015


    BILIARY:

    SWOG S1310
    Randomized Phase II Trial of Single Agent MEK Inhibitor (GSK1120212) vs. 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer

    Back to top


    BRAIN:

    N107C
    Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease

    Back to top


    BREAST:

    S1007
    A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

    SWOG 1202
    A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer

    SWOG 1207 / NSABP B-53
    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (Breast Cancer Study – evaluating everolimus with endocrine therapy)

    Back to top


    GASTROINTESTINAL:

    CALGB 80702
    A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

    Back to top


    GENITOURINARY:

    RTOG 0534
    A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy

    RTOG 0815
    A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

    RTOG 0924
    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

    S0931
    EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

    S1216
    A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

    Back to top


    Gynecologic

    GOG-0238
    A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterus Corpus

    GOG-0263
    A Randomized Phase III Clinical Trial of Adjuvant Radiation vs. Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

    Back to top


    HEAD & NECK:

    E1305
    A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab In Patients with Recurrent Or Metastatic Head and Neck Cancer

    RTOG 0920
    A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

    Back to top


    LYMPHOMA

    E1412
    Randomized phase II Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

    Back to top


    THORAX:

    E5508
    A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small Cell Lung Cancer

    CALGB 30610
    Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

    Back to top

    Contacts

    For additional information regarding the above Clinical Trials,
    please contact one of our Cancer Research Coordinators:

    Elise Fredeking, RN, BSN, OCN
    209-526-4500, ext. 6192

    Denise Galbawy, RN, BSN, OCN, CCRC
    209-572-7116.